Bioton

Bioton EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Bioton (BIO.WA) as of Oct 21, 2026 is 28.02. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -62.87 — a change of -144.56% (higher).

EV/EBIT

28.02

YoY

-144.56%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Bioton is 2025 28.02 . EV/EBIT (Enterprise Value to EBIT) of Bioton was 2024 -62.87 . It decreases by -144.56% higher compared to the previous year.

The Bioton EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBIT
Date
EV/EBIT
Jan 1, 2019
-2.32 PLN
Jan 1, 2020
7.39 PLN
Jan 1, 2021
18.91 PLN
Jan 1, 2022
26.79 PLN
Jan 1, 2023
22.92 PLN
Jan 1, 2024
-62.87 PLN
Jan 1, 2025
28.02 PLN
Jan 1, 2026 (e)
14.19 PLN
The Bioton EV/EBIT history
YEAREV/EBITYoY
est14.19-49.35%
28.02-144.56%
-62.87-374.32%
22.92-14.46%
26.79+41.69%
18.91+155.94%
7.39-417.91%
-2.32-115.02%
15.47-22.27%
19.91-177.06%
-25.83+3,519.22%
-0.71-104.40%
16.24+4.55%
15.53+42.35%
10.91-269.41%
-6.44-161.69%
10.44-649.47%
-1.90-92.09%
-24.02-131.51%
76.24-69.51%
250.06—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bioton Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Bioton's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Bioton's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Bioton's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Bioton grows earnings faster than its peers.

Bioton Stock analysis

What does Bioton do? Bioton SA is a leading Polish biotechnology company specializing in the development of innovative drugs, diagnostics, and medical devices. The company was founded in 1989 and has since achieved remarkable success. Bioton is headquartered in Poland and employs approximately 1000 people worldwide. The company is listed on the Warsaw Stock Exchange and is supported by renowned investors. Business model Bioton operates various business divisions, including research and development, production, sales, as well as marketing and distribution. The company collaborates closely with leading academic institutions and research organizations and invests significant resources in the development of new groundbreaking technologies and products. The company's products and services are distributed and used in over 60 countries worldwide. Divisions Bioton is divided into three main business sectors, including biopharmaceuticals, diagnostics, and medical devices. Biopharmaceuticals Bioton is known for its biopharmaceuticals, particularly insulin and insulin analogs. Insulin is a hormone produced by the body to regulate blood sugar levels. Bioton offers various insulin products, including human insulin, insulin glargine, and insulin aspart. These products are approved for the treatment of diabetes mellitus and are distributed in over 50 countries worldwide. Diagnostics Bioton is also involved in the development and production of diagnostics. The company offers various testing systems for the diagnosis of infectious diseases, allergies, and autoimmune diseases. The product line also includes in vitro diagnostics that are used for medical therapy monitoring and disease detection. Medical devices Bioton also manufactures and distributes medical devices such as insulin pumps and blood glucose meters. These devices are designed for people with diabetes and assist in accurate insulin dosing and blood sugar level monitoring. Products In addition to insulin and insulin analogs, Bioton also produces a wide range of other drugs, including growth hormones, as well as follicle-stimulating hormone (FSH) and luteinizing hormone (LH). These hormones are used for the treatment of infertility. Bioton is also involved in the development of novel technologies such as RNA interference (RNAi) and genomic research. The company invests significantly in innovative research projects aimed at the development of groundbreaking drugs and therapies. In conclusion, Bioton SA is a highly innovative biotechnology company with a wide range of products and a focus on research and development. The company operates in the global market and collaborates closely with renowned institutions and research organizations. Bioton's business model is based on the development of innovative technologies and products aimed at improving the quality of life for people worldwide. Bioton is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bioton stock

EV/EBIT (Enterprise Value to EBIT) of Bioton is 28.02 in 2025.

EV/EBIT (Enterprise Value to EBIT) of Bioton changed from -62.87 to 28.02, representing a -144.56% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) Bioton since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s Bioton with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Bioton

All Key Metrics — Bioton